 Amit Reddy
Concepts (120)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Uveitis | 9 | 2025 | 150 | 3.730 |
Why?
| | Fluocinolone Acetonide | 3 | 2024 | 15 | 2.320 |
Why?
| | Scleritis | 5 | 2025 | 28 | 2.070 |
Why?
| | Visual Acuity | 9 | 2026 | 490 | 1.980 |
Why?
| | Glucocorticoids | 6 | 2026 | 532 | 1.680 |
Why?
| | Eye Infections, Viral | 2 | 2026 | 12 | 1.170 |
Why?
| | Uveitis, Anterior | 2 | 2026 | 27 | 1.150 |
Why?
| | Macular Edema | 3 | 2026 | 49 | 1.140 |
Why?
| | Intravitreal Injections | 2 | 2026 | 71 | 1.070 |
Why?
| | Drug Implants | 2 | 2024 | 83 | 1.000 |
Why?
| | Uveitis, Intermediate | 2 | 2023 | 8 | 0.960 |
Why?
| | Retinal Vasculitis | 1 | 2026 | 12 | 0.940 |
Why?
| | Corneal Ulcer | 2 | 2022 | 20 | 0.910 |
Why?
| | Ocular Hypertension | 1 | 2026 | 70 | 0.880 |
Why?
| | Herpesvirus 4, Human | 1 | 2026 | 172 | 0.880 |
Why?
| | Pemphigoid, Benign Mucous Membrane | 1 | 2024 | 6 | 0.860 |
Why?
| | Epstein-Barr Virus Infections | 1 | 2026 | 101 | 0.860 |
Why?
| | Withholding Treatment | 1 | 2025 | 80 | 0.850 |
Why?
| | Tuberculosis, Ocular | 1 | 2024 | 8 | 0.830 |
Why?
| | Interferon-gamma Release Tests | 1 | 2024 | 32 | 0.810 |
Why?
| | Keratoconjunctivitis Sicca | 1 | 2022 | 4 | 0.750 |
Why?
| | Cataract Extraction | 1 | 2023 | 120 | 0.710 |
Why?
| | Sarcoidosis | 1 | 2023 | 163 | 0.670 |
Why?
| | Cataract | 1 | 2023 | 238 | 0.640 |
Why?
| | Uveitis, Posterior | 1 | 2019 | 12 | 0.580 |
Why?
| | Tomography, Optical Coherence | 4 | 2026 | 270 | 0.550 |
Why?
| | Multiple Sclerosis | 1 | 2023 | 489 | 0.520 |
Why?
| | Follow-Up Studies | 8 | 2026 | 5428 | 0.510 |
Why?
| | Phacoemulsification | 1 | 2019 | 123 | 0.510 |
Why?
| | Conjunctiva | 1 | 2016 | 52 | 0.460 |
Why?
| | Eyelid Diseases | 1 | 2016 | 26 | 0.460 |
Why?
| | Retrospective Studies | 11 | 2026 | 17330 | 0.460 |
Why?
| | Mycophenolic Acid | 3 | 2025 | 119 | 0.440 |
Why?
| | Eye Infections, Bacterial | 2 | 2025 | 45 | 0.430 |
Why?
| | Intraocular Pressure | 3 | 2026 | 330 | 0.430 |
Why?
| | Methotrexate | 3 | 2025 | 233 | 0.420 |
Why?
| | Arthritis, Rheumatoid | 1 | 2022 | 1180 | 0.390 |
Why?
| | Aged | 9 | 2026 | 26217 | 0.340 |
Why?
| | Immunosuppressive Agents | 3 | 2025 | 838 | 0.330 |
Why?
| | Fluorescein Angiography | 3 | 2026 | 189 | 0.320 |
Why?
| | Humans | 23 | 2026 | 145785 | 0.310 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2024 | 2028 | 0.290 |
Why?
| | Male | 16 | 2026 | 73012 | 0.290 |
Why?
| | Risk Assessment | 1 | 2019 | 3752 | 0.290 |
Why?
| | Female | 14 | 2026 | 79045 | 0.280 |
Why?
| | Adalimumab | 2 | 2025 | 54 | 0.260 |
Why?
| | Middle Aged | 9 | 2026 | 36309 | 0.250 |
Why?
| | Pars Planitis | 1 | 2026 | 6 | 0.240 |
Why?
| | Postoperative Complications | 1 | 2019 | 2977 | 0.230 |
Why?
| | Leprosy, Lepromatous | 1 | 2025 | 8 | 0.230 |
Why?
| | Keratitis | 1 | 2025 | 20 | 0.230 |
Why?
| | Vitreous Body | 2 | 2025 | 117 | 0.230 |
Why?
| | Aqueous Humor | 1 | 2025 | 40 | 0.220 |
Why?
| | Azathioprine | 1 | 2025 | 44 | 0.220 |
Why?
| | Antibodies, Bispecific | 1 | 2026 | 68 | 0.220 |
Why?
| | Tertiary Care Centers | 1 | 2026 | 195 | 0.220 |
Why?
| | Endophthalmitis | 1 | 2025 | 46 | 0.220 |
Why?
| | Lubricant Eye Drops | 1 | 2024 | 9 | 0.220 |
Why?
| | Uveomeningoencephalitic Syndrome | 1 | 2024 | 7 | 0.210 |
Why?
| | Infliximab | 1 | 2025 | 111 | 0.210 |
Why?
| | Macula Lutea | 1 | 2024 | 21 | 0.210 |
Why?
| | Conjunctivitis | 1 | 2024 | 30 | 0.210 |
Why?
| | Angiogenesis Inhibitors | 1 | 2026 | 239 | 0.210 |
Why?
| | Ophthalmic Solutions | 1 | 2024 | 82 | 0.210 |
Why?
| | Metagenomics | 1 | 2025 | 150 | 0.200 |
Why?
| | Endemic Diseases | 1 | 2024 | 33 | 0.200 |
Why?
| | Diabetic Retinopathy | 1 | 2026 | 211 | 0.200 |
Why?
| | Adult | 9 | 2025 | 40882 | 0.190 |
Why?
| | Granuloma | 1 | 2023 | 97 | 0.190 |
Why?
| | Polypropylenes | 1 | 2022 | 12 | 0.190 |
Why?
| | Biological Factors | 1 | 2022 | 39 | 0.180 |
Why?
| | Immunologic Factors | 1 | 2024 | 260 | 0.180 |
Why?
| | Sutures | 1 | 2022 | 66 | 0.180 |
Why?
| | Treatment Outcome | 3 | 2025 | 11794 | 0.170 |
Why?
| | Mycobacterium tuberculosis | 1 | 2024 | 318 | 0.160 |
Why?
| | Young Adult | 4 | 2026 | 14254 | 0.160 |
Why?
| | Granuloma, Foreign-Body | 1 | 2020 | 8 | 0.150 |
Why?
| | Tattooing | 1 | 2020 | 12 | 0.150 |
Why?
| | Adrenal Cortex Hormones | 1 | 2023 | 484 | 0.150 |
Why?
| | Aged, 80 and over | 3 | 2024 | 8347 | 0.150 |
Why?
| | Anti-Inflammatory Agents | 1 | 2022 | 478 | 0.140 |
Why?
| | Predictive Value of Tests | 1 | 2024 | 2123 | 0.140 |
Why?
| | Adolescent | 4 | 2026 | 22577 | 0.140 |
Why?
| | Anti-Bacterial Agents | 2 | 2025 | 1925 | 0.120 |
Why?
| | Biopsy | 2 | 2020 | 1082 | 0.120 |
Why?
| | Histiocytes | 1 | 2016 | 7 | 0.120 |
Why?
| | Immunoglobulins | 1 | 2016 | 163 | 0.110 |
Why?
| | Neck Injuries | 1 | 2015 | 21 | 0.110 |
Why?
| | Complement C3 | 1 | 2016 | 187 | 0.110 |
Why?
| | Fibrinogen | 1 | 2016 | 180 | 0.110 |
Why?
| | Wounds, Penetrating | 1 | 2015 | 72 | 0.110 |
Why?
| | Registries | 1 | 2023 | 2410 | 0.100 |
Why?
| | Respiratory System | 1 | 2015 | 150 | 0.100 |
Why?
| | Computed Tomography Angiography | 1 | 2015 | 146 | 0.100 |
Why?
| | Lymphocytes | 1 | 2016 | 376 | 0.100 |
Why?
| | Colorado | 1 | 2024 | 4556 | 0.100 |
Why?
| | United States | 2 | 2023 | 16126 | 0.100 |
Why?
| | Child, Preschool | 2 | 2026 | 11868 | 0.090 |
Why?
| | Immunohistochemistry | 1 | 2016 | 1723 | 0.090 |
Why?
| | Incidence | 1 | 2019 | 2934 | 0.090 |
Why?
| | Neutrophils | 1 | 2016 | 1127 | 0.080 |
Why?
| | Child | 3 | 2026 | 22740 | 0.080 |
Why?
| | Infant | 1 | 2022 | 10091 | 0.070 |
Why?
| | Atrophy | 1 | 2025 | 199 | 0.050 |
Why?
| | Risk Factors | 1 | 2019 | 10919 | 0.050 |
Why?
| | Retinal Pigment Epithelium | 1 | 2024 | 79 | 0.050 |
Why?
| | Retinal Detachment | 1 | 2024 | 73 | 0.050 |
Why?
| | Drug Therapy, Combination | 1 | 2025 | 1043 | 0.050 |
Why?
| | High-Throughput Nucleotide Sequencing | 1 | 2025 | 534 | 0.040 |
Why?
| | Reference Standards | 1 | 2022 | 177 | 0.040 |
Why?
| | Systemic Inflammatory Response Syndrome | 1 | 2022 | 95 | 0.040 |
Why?
| | Foreign-Body Reaction | 1 | 2020 | 34 | 0.040 |
Why?
| | Bacteria | 1 | 2025 | 766 | 0.040 |
Why?
| | Steroids | 1 | 2020 | 160 | 0.040 |
Why?
| | Double-Blind Method | 1 | 2023 | 2064 | 0.030 |
Why?
| | Neck | 1 | 2015 | 109 | 0.030 |
Why?
| | Pandemics | 1 | 2022 | 1711 | 0.020 |
Why?
| | Sensitivity and Specificity | 1 | 2015 | 2000 | 0.020 |
Why?
| | Algorithms | 1 | 2015 | 1851 | 0.020 |
Why?
| | Reproducibility of Results | 1 | 2015 | 3418 | 0.020 |
Why?
|
|
Reddy's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|